InMed Pharmaceuticals Inc. INM
1.38
(0.02)
(1.43%)
as of 25 Sep
- Market cap
- $7.7M
- P/E
- 0.0×
Follow INM
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(82.17%) | (97.20%) | (122.32%) | (179.09%) | |
| (68.92%) | (77.83%) | (92.43%) | (139.63%) | ||
ROIC |
(156.22%) | (138.03%) | (244.94%) | 0.00% | |
Return on Tangible Assets |
(81.09%) | (94.94%) | (159.97%) | (1,378.37%) | |
Average Days of Receivables |
20.69 | 11.58 | — | — | |
Free Cash Flow per Share |
(1.99) | (1.96) | (1.92) | (2.08) | |
Free Cash Flow |
(7.88) | (7.75) | (7.79) | (8.64) | |
Piotroski F-Score |
4.00 | 3.00 | — | — | |
| Other line items | |||||
Cash ROIC |
(37.21%) | (46.41%) | (64.26%) | (261.20%) | |
Accounts Receivable Turnover |
19.29 | 25.89 | — | — | |
Accounts Payable Turnover |
3.99 | 3.48 | 0.00 | 0.00 | |
Inventory Turnover |
4.04 | 4.15 | — | — | |
Average Days of Payables |
96.66 | 91.99 | 0.00 | 0.00 | |
Days of Inventory on Hand |
76.18 | 81.35 | — | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
44.60% | 42.27% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
90.00% | 92.85% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
1.82% | 1.95% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.96 | 1.01 | 0.92 | 0.67 | |
Depreciation/Fixed assets |
0.24 | 0.28 | 0.33 | 0.93 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
1.53 | 1.46 | 0.00 | 0.00 | |
Operating CF per Share |
(1.99) | (1.96) | (1.92) | (2.08) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Net Profit Margin |
(135.50%) | (132.87%) | 0.00% | 0.00% |
Columns are period end dates